KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Halozyme Therapeutics (HALO) over the last 14 years, with Q4 2025 value amounting to $123.9 million.

  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) fell 426.51% to $123.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $123.9 million, marking a year-over-year decrease of 426.51%. This contributed to the annual value of $123.9 million for FY2025, which is 426.51% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Shares Outstanding (Diluted Average) of $123.9 million as of Q4 2025, which was down 426.51% from $124.4 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Shares Outstanding (Diluted Average) peaked at $148.5 million during Q1 2021, and registered a low of $123.9 million during Q4 2025.
  • Over the past 5 years, Halozyme Therapeutics' median Shares Outstanding (Diluted Average) value was $135.5 million (recorded in 2023), while the average stood at $135.9 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Shares Outstanding (Diluted Average) surged by 827.64% in 2021, and later plummeted by 653.59% in 2024.
  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $146.8 million in 2021, then dropped by 4.22% to $140.6 million in 2022, then fell by 4.56% to $134.2 million in 2023, then fell by 3.56% to $129.4 million in 2024, then decreased by 4.27% to $123.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $123.9 million in Q4 2025, compared to $124.4 million in Q3 2025 and $125.5 million in Q2 2025.